![Michael Atkin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Atkin
Directeur Général chez
Ulysses Pharmaceuticals Products, Inc.
Profil
Michael C.
Atkin is the founder of Syzent Partners Ltd. founded in 2008, where he holds the title of President.
He currently holds the positions of Executive Chairman, President & CEO at Ulysses Pharmaceuticals Products, Inc. and Director at Affinite Instruments.
Mr. Atkin's former positions include President & Chief Executive Officer at Aegera Therapeutics, Inc., President, Chief Executive Officer & Secretary at Gladius Pharmaceuticals Corp., Chairman at ChitogenX, Inc., Chairman at Sopharmia, Inc., Director at Genizon Biosciences, Inc., Director at Topigen Pharmaceuticals, Inc., and Principal at Bristol Myers Squibb Co. He also held the position of Vice President-Business Development at Lederle International.
Mr. Atkin received his undergraduate degree from the University of Kent and his MBA from Columbia Business School.
Postes actifs de Michael Atkin
| Sociétés | Poste | Début |
|---|---|---|
Ulysses Pharmaceuticals Products, Inc.
 Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections | Directeur Général | - |
Syzent Partners Ltd. | Fondateur | 01/01/2008 |
Affinite Instruments | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Atkin
| Sociétés | Poste | Fin |
|---|---|---|
| CHITOGENX INC. | Président | 01/07/2022 |
Gladius Pharmaceuticals Corp.
 Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Operates as biotechnology firm | Directeur Général | 01/01/2019 |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Provides drug development services | Directeur/Membre du Conseil | 30/05/2012 |
Sopharmia, Inc. | Président | - |
Lederle International | Corporate Officer/Principal | - |
Formation de Michael Atkin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Provides drug development services | Health Technology |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and develops drugs | Health Technology |
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for respiratory diseases | Health Technology |
Lederle International | |
Ulysses Pharmaceuticals Products, Inc.
Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections | Health Technology |
University of Kent
 University of Kent Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Operates as biotechnology firm | Health Technology |
ChitogenX, Inc.
 ChitogenX, Inc. BiotechnologyHealth Technology Operates as a development stage biotechnology company | Health Technology |
Syzent Partners Ltd. | |
Sopharmia, Inc. | |
Affinite Instruments |
